Medtronic Bolsters Sinus Portfolio With $1.1Bn Intersect ENT Buyout
Medtronic announced plans to acquire Intersect ENT, adding its sinus implants to Medtronic's portfolio of devices used by surgeons in treating chronic rhinosinusitis.
You may also be interested in...
The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
The company reported its progress in key environmental, social, and governance areas over the past year along with some new performance targets related to sustainability and inclusion. Medtronic also added a new “tagline” to its brand.